Company / R&D Expense
Inhibrx Biosciences, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$113.0M
FY2025
5-year range
$113.0M / $191.6M
FY2023-FY2025
Trend
-41.0%
vs FY2024
Sector context
#134 of 210
Health Care
What the data says
At $113M, Inhibrx Biosciences, Inc.'s r&d expense ranks #134 of 210 in the Health Care sector. Declined from $192M to $113M over the past 2 years.
Based on SEC 10-K filings.
$113M in FY2025.
Declined from $192M to $113M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#134 of 210 in Health CareTop 64% of 210This company $113.0M Sector average $644.1M
▼
-82.5% below sector average
Key checks
Key Insights
- In FY2025, r&d expense decreased 41.0% year-over-year.
- Ranks #134 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.77 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $113.0M | -41.0% |
| FY2024 | $191.6M | +0.0% |
| FY2023 | $191.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026